Pages that link to "Q29393835"

The following pages link to Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations (Q29393835):

Displaying 50 items.

• Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis (Q21198704) (← links)
• Teratogenic mechanisms of medical drugs (Q22337136) (← links)
• The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key? (Q26741187) (← links)
• Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation (Q26795384) (← links)
• Drugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risks (Q26991704) (← links)
• Antidepressant use in pregnancy: a critical review focused on risks and controversies (Q28281407) (← links)
• Prenatal antidepressant exposure: clinical and preclinical findings (Q30415540) (← links)
• Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy--an epidemiological study using validated EUROCAT data (Q30855293) (← links)
• Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data (Q33521786) (← links)
• Serotonin transport and metabolism in the mammary gland modulates secretory activation and involution (Q33736087) (← links)
• Prenatal exposure to serotonin reuptake inhibitors: a case report (Q33763631) (← links)
• Antidepressant use in pregnancy and the risk of cardiac defects (Q33775616) (← links)
• Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects (Q33801507) (← links)
• Maternal use of selective serotonin reuptake inhibitors during pregnancy is associated with Hirschsprung's disease in newborns - a nationwide cohort study. (Q33816388) (← links)
• Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. (Q33896573) (← links)
• The fetal safety of fluoxetine: a systematic review and meta-analysis. (Q34036622) (← links)
• Paroxetine use in pregnancy and increased risk of heart defects: Evaluating the evidence. (Q34062619) (← links)
• Antidepressant use in pregnant and postpartum women (Q34068023) (← links)
• Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis (Q34144128) (← links)
• Treatment of nonpsychotic major depression during pregnancy: patient safety and challenges (Q34237681) (← links)
• The Nordic health registers - an important source when evaluating the safety of antidepressants during pregnancy (Q34240630) (← links)
• The management of mood disorders in pregnancy: alternatives to antidepressants (Q34338163) (← links)
• Early pregnancy exposure to selective serotonin reuptake inhibitors, risks of major structural malformations, and hypothesized teratogenic mechanisms (Q34483257) (← links)
• A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction (Q34514870) (← links)
• Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study. (Q34516341) (← links)
• Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines (Q34590507) (← links)
• Clinical risk factors for gastroschisis and omphalocele in humans: a review of the literature (Q34623055) (← links)
• The safety of antidepressant drugs during pregnancy (Q34661348) (← links)
• Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort study (Q34702282) (← links)
• Perinatal depression: implications for child mental health (Q34870012) (← links)
• The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists (Q34981937) (← links)
• We don't know what we don't study: The case for research on medication effects in pregnancy (Q35119048) (← links)
• Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design (Q35541040) (← links)
• Low-dose paroxetine exposure causes lifetime declines in male mouse body weight, reproduction and competitive ability as measured by the novel organismal performance assay (Q35561318) (← links)
• The problem of confounding in studies of the effect of maternal drug use on pregnancy outcome (Q35608879) (← links)
• Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat? (Q35608913) (← links)
• Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re‐uptake inhibitors and tricyclic antidepressants. Part 1: Literature review (Q35640425) (← links)
• Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007. (Q35794715) (← links)
• Effects of Citalopram on Sutural and Calvarial Cell Processes. (Q35796871) (← links)
• Use of prescription medicines in Australian women of child-bearing age. (Q35862755) (← links)
• Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study (Q36045075) (← links)
• Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Congenital Heart Defects: A Meta-Analysis of Prospective Cohort Studies (Q36141324) (← links)
• Neonatal and childhood neurodevelopmental, health and educational outcomes of children exposed to antidepressants and maternal depression during pregnancy: protocol for a retrospective population-based cohort study using linked administrative data (Q36207250) (← links)
• Prescribing without evidence - pregnancy (Q36336002) (← links)
• In utero exposure to antidepressants and the use of drugs for pulmonary diseases in children (Q36609764) (← links)
• The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis (Q36706789) (← links)
• Perinatal depression: treatment options and dilemmas. (Q36737979) (← links)
• The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring (Q36860205) (← links)
• The safety of pharmacological therapies for gastrointestinal conditions encountered during pregnancy (Q36945003) (← links)
• Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study (Q37142457) (← links)